Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15.05. | Abpro Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
27.04. | Abpro Corporation: Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager | 124 | GlobeNewswire (Europe) | Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profileAbpro and Celltrion have a strategic partnership for worldwide development and commercialization... ► Artikel lesen | |
24.04. | Abpro Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
15.04. | Abpro Holdings, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
15.04. | Abpro Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
08.04. | Abpro Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
01.04. | Abpro Holdings, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 3 | SEC Filings | ||
ABPRO Aktie jetzt für 0€ handeln | |||||
26.03. | Abpro Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
25.03. | Abpro Corporation: Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025 | 1 | GlobeNewswire (USA) | ||
10.03. | Abpro Corporation: Abpro Statement on the Departure of Former CEO Ian Chan | 144 | GlobeNewswire (Europe) | WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening... ► Artikel lesen | |
07.03. | Abpro Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
21.02. | Abpro Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
07.02. | Abpro Holdings, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
23.12.24 | Abpro Holdings, Inc. - S-1, General form for registration of securities | 3 | SEC Filings | ||
19.12.24 | Pre-market Movers: PainReform, CURRENC Group, Bio-Path Holdings, Abpro Corporation, KULR Technology | 984 | AFX News | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green PainReform Ltd. (PRFX) is up over... ► Artikel lesen | |
12.12.24 | Abpro Corporation: Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing | 2 | GlobeNewswire (USA) | ||
12.12.24 | Abpro Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
13.11.24 | Abpro Announces Closing of Business Combination with Atlantic Coastal Acquisition Corp. II | 158 | PR Newswire | Abpro Expected to Begin Trading on Nasdaq on Thursday, November 14, 2024, Under the Tickers "ABP" and "ABPWW"
WOBURN, Mass. and NEW YORK, Nov. 13, 2024 /PRNewswire/... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SPRINGWORKS THERAPEUTICS | 46,710 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN | - im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN -
- die Entscheidung der Europäischen Kommission... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 34,220 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 15,520 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
ARCELLX | 65,48 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 28,880 | 0,00 % | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | ||
BIONTECH | 98,95 | +1,49 % | BioNTech: Milliardendeal mit Bristol Myers Squibb - Aktie schießt ins Plus | BioNTechs Aktien schießen in der US-Vorbörse am Montag regelrecht nach oben: Aktuell werden 106,10 Dollar notiert nach einem NASDAQ-Schlusskurs bei 95,81 Dollar vom Freitag. Der Grund für den Kursanstieg... ► Artikel lesen | |
ENLIVEN THERAPEUTICS | 22,290 | 0,00 % | Mizuho erhöht Kursziel für Enliven Therapeutics-Aktie auf 41 US-Dollar | ||
DISC MEDICINE | 47,320 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update | Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with... ► Artikel lesen | |
APOGEE THERAPEUTICS | 36,500 | 0,00 % | Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results | Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in... ► Artikel lesen | |
ADMA BIOLOGICS | 20,330 | -0,64 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
QIAGEN | 40,290 | -0,09 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 48 Euro auf "Buy" belassen. Der Tenor auf der Berenberg-MedTech-Investorenkonferenz in Manhatten... ► Artikel lesen | |
89BIO | 10,050 | 0,00 % | 89bio hält Jahreshauptversammlung ab, Direktoren gewählt | ||
ARCUTIS BIOTHERAPEUTICS | 13,260 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung und 19 US-Dollar Kursziel für Arcutis-Aktie | ||
KYMERA THERAPEUTICS | 44,310 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile... ► Artikel lesen | |
FULCRUM THERAPEUTICS | 7,030 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics to Present at Upcoming Medical Meetings |